The EPS miss is noise on a tiny base; the story is the 38% revenue growth, margin expansion, and FDA 510(k) timeline. Monitor for the FDA submission in H2 2026 and any updates on U.S. market entry, which is the primary catalyst for this stock.
Price Chart
Executive Summary
Intelligent Bio Solutions reported fiscal 2026 full-year revenue of $4.2M, up 38% YoY, with gross margin expanding 778 bps to 48.63%. The company is pre-revenue in the U.S. and remains deeply unprofitable, with net loss widening to $12.4M. The EPS miss is a mechanical artifact of share count changes on a tiny base. The stock's move hinges on the FDA 510(k) submission timeline (H2 2026) and commercial traction in international markets, not the EPS surprise.
Key Financial Metrics
Key Facts
- Full-year revenue $4,215,175, up 38% YoY from $3,052,532.
- Gross profit margin expanded to 48.63% from 40.85%, a 778 bps improvement.
- Net loss attributable to INBS widened to $12,430,975 from $10,568,733.
- EPS was -$8.44 vs consensus of -$1.58 (a 434% miss), but this is a mechanical artifact of share count changes on a tiny base.
- Reader installed base grew 22% to 1,886 units; consumable cartridges up 35% to 106,500 units.
- 502 active customers as of June 30, 2026.
- FDA 510(k) submission on track for H2 2026.
- Cash and equivalents $3.99M vs $1.02M a year ago.
Financial Impact
Revenue growth of 38% to $4.2M, gross margin expansion to 48.63%, but net loss widened by $1.86M to $12.4M.
Risk Factors
- FDA 510(k) submission may be delayed or denied, preventing U.S. market entry.
- Cash burn continues; $3.99M cash may require additional financing before reaching profitability.
- International commercial traction may not sustain at current growth rates.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-039140 |
| Document: form8-k.htm | 0001493152-26-039140 |
| Document: 0001493152-26-039140-index-headers.html | 0001493152-26-039140 |
| Document: 0001493152-26-039140-index.html | 0001493152-26-039140 |
| Document: 0001493152-26-039140.txt | 0001493152-26-039140 |
| 8-K Data (Synthetic) | 0001493152-26-039140 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 6d ago | 10-K/A | $1.69 | awaiting T+20 | — | $1.64 (−2.67%) |
Oct 13, 2026 14d ago | 8-K | $1.45 | awaiting T+20 | — | $1.64 (+13.10%) |
Sep 24, 2026 4w ago | EFFECT | $1.71 $1.69 | ▲ +1.46% | ▲ +1.04% | $1.64 (+4.09%) |
Sep 15, 2026 6w ago | S-3 | $1.97 $1.48 | ▼ −24.87% | ▼ −28.05% | $1.64 (−16.75%) |
Sep 11, 2026 6w ago | 8-K | $2.07 $1.51 | ▼ −27.05% | ▼ −29.32% | $1.64 (−20.77%) |
Sep 9, 2026 6w ago | 8-K | $2.24 $1.59 | ▼ −29.02% | ▼ −30.96% | $1.64 (−26.79%) |
Sep 2, 2026 7w ago | 8-K | $2.30 $1.66 | ▲ +27.83% | ▲ +26.64% | $1.64 (+28.70%) |
Aug 19, 2026 9w ago | 8-K | $2.67 $2.05 | ▼ −23.22% | ▼ −21.70% | $1.64 (−38.58%) |
Aug 19, 2026 9w ago | Press Release | $2.67 $2.05 | ▲ +23.22% | ▲ +21.70% | $1.64 (+38.58%) |
Aug 17, 2026 10w ago | Press Release | $3.37 $2.05 | ▼ −39.17% | ▼ −37.19% | $1.64 (−51.34%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers